Floatz logo

CR3+

Polycystic Ovary Syndrome

Beni-Suef UniversitySmall moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

65 Active assets in the Polycystic Ovary Syndrome cohort.

Asset / SponsorPhaseRating
Semaglutide
Methodist Health System
Phase 4BBB
Hcg
Eman Basuni Ebrahim Mowad
Phase 4BBB
Liraglutide
Peking University Third Hospital
Phase 4BBB
FOLLITROPIN BETA
Universitair Ziekenhuis Brussel
Phase 4BBB
Drospirenone
Ege University
Phase 4BBB

View all 50 →

Same molecule, other indications

CR3+ is also rated in:

Diabetes Mellitus, Type 2Dormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →